

CLINICAL TRIALS AND OBSERVATIONS

CME Article

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Ayalew Tefferi,¹ Paola Guglielmelli,² Dirk R. Larson,³ Christy Finke,¹ Emnet A. Wassie,¹ Lisa Pieri,² Naseema Gangat,¹ Rajmonda Fjerza,² Alem A. Belachew,¹ Terra L. Lasho,¹ Rhett P. Ketterling,⁴ Curtis A. Hanson,⁵ Alessandro Rambaldi,⁶ Guido Finazzi,⁶ Juergen Thiele,⁷ Tiziano Barbui,⁶ Animesh Pardhanani,¹ and Alessandro M. Vannucchi²

¹Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN; ²Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; ³Department of Statistics and Bioinformatics, ⁴Division of Cytogenetics, Department of Laboratory Medicine, and ⁵Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN; ⁶Division of Hematology and Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy; and ⁷Institute of Pathology, University of Cologne, Cologne, Germany

Key Points

- Survival in ET is superior to that of PV, regardless of mutational status, but remains inferior to the sex- and age-matched US population.
- *JAK2/CALR/MPL* mutational status is prognostically informative in PMF, regarding overall and leukemia-free survival.

Janus kinase 2 (*JAK2*) mutations define polycythemia vera (PV). Calreticulin (*CALR*) and myeloproliferative leukemia virus oncogene (*MPL*) mutations are specific to *JAK2*-unmutated essential thrombocythemia (ET) and primary myelofibrosis (PMF). We examined the effect of these mutations on long-term disease outcome. One thousand five hundred eighty-one patients from the Mayo Clinic (n = 826) and Italy (n = 755) were studied. Fifty-eight percent of Mayo patients were followed until death; median survivals were 19.8 years in ET (n = 292), 13.5 PV (n = 267; hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.4-2.2), and 5.9 PMF (n = 267; HR, 4.5; 95% CI, 3.5-5.7). The survival advantage of ET over PV was not affected by *JAK2/CALR/MPL* mutational status. Survival in ET was inferior to the age- and sex-matched US population (P < .001). In PMF (n = 428), but not in ET (n = 576), survival and blast transformation (BT) were significantly affected by mutational status; outcome was best in *CALR*-mutated and worst in triple-negative patients: median survival, 16 vs 2.3 years (HR, 5.1; 95% CI, 3.2-8.0) and BT, 6.5% vs 25% (HR, 7.6; 95% CI, 2.8-20.2), respectively. We conclude that life expectancy in morphologically defined ET is significantly reduced but remains superior to that of PV, regardless of mutational status. In PMF, *JAK2/CALR/MPL* mutational status is prognostically informative. (*Blood*. 2014;124(16):2507-2513)

Medscape Continuing Medical Education online

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medscape, LLC and the American Society of Hematology.

Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at <http://www.medscape.org/journal/blood>; and (4) view/print certificate. For CME questions, see page 2615.

Disclosures

The authors, Associate Editor Jacob M. Rowe, and CME questions author Laurie Barclay, freelance writer and reviewer, Medscape, LLC, declare no competing financial interests.

Learning objectives

1. Compare survival outcomes in essential thrombocythemia vs polycythemia vera, based on a large, retrospective cohort study.
2. Describe the associations of *JAK2/CALR/MPL* mutational status in primary myelofibrosis with overall and leukemia-free survival.
3. Distinguish the clinical and research implications of the findings of this large, retrospective cohort study on survival outcomes in myeloproliferative neoplasms.

Release date: October 16, 2014; Expiration date: October 16, 2015

Submitted May 29, 2014; accepted July 8, 2014. Prepublished online as *Blood* First Edition paper, July 18, 2014; DOI 10.1182/blood-2014-05-579136.

The online version of this article contains a data supplement.

There is an Inside *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2014 by The American Society of Hematology

Introduction

Janus kinase 2 (*JAK2*) mutations are present in >95% of patients with polycythemia vera (PV) and also constitute the most frequent mutation (~60% incidence) in essential thrombocythemia (ET) and primary myelofibrosis (PMF).¹ Calreticulin (*CALR*) exon 9 insertions/deletions represent the second most frequent mutation in ET and PMF; their mutational frequency is estimated between 15% and 32% in ET and 25% and 35% in PMF.²⁻⁸ Myeloproliferative leukemia virus oncogene (*MPL*) mutations are also specific to ET and PMF and occur with mutational frequencies of 4% in ET and ~8% in PMF.¹ *JAK2*, *CALR*, and *MPL* mutations are for the most part mutually exclusive and their pathogenetic contribution is currently believed to include upregulation of *JAK2* signaling.⁹

The original descriptions of *CALR* mutations in myeloproliferative neoplasms (MPN) suggested a significant impact on disease phenotype and outcome.^{2,3} In 1 of these 2 seminal reports,² *CALR*-mutated patients with ET, compared with their *JAK2*-mutated counterparts, displayed higher platelet count, lower leukocyte count, lower hemoglobin level, lower risk of thrombosis, and better survival. The authors also reported higher platelet count, lower leukocyte count, and better survival in *CALR*-mutated PMF patients, compared with *JAK2*-mutated cases.² In the second study,³ *CALR*-mutated ET patients were associated with higher platelet count, lower hemoglobin level, and higher incidence of fibrotic transformation, compared with *JAK2*-mutated cases.³

Subsequent reports did not find significant difference in survival or risk of fibrotic transformation between *CALR*- and *JAK2*-mutated ET.^{4,5,7} In PMF, the favorable impact of *CALR* mutations on survival² was confirmed in a subsequent study,⁶ which also disclosed the prognostically detrimental effect of “triple-negative” mutational status (ie, wild type for *JAK2*, *CALR* and *MPL*). The latter study⁶ and subsequent reports^{10,11} showed further prognostic modifications by *ASXL1* mutational status and number of prognostically detrimental mutations. Mutant *CALR* vs *JAK2* mutations in PMF were also associated with younger age, lower hemoglobin level, lower risk disease, and lower frequency of spliceosome mutations.⁶ More recent reports have suggested differential phenotypic and prognostic effects from distinct mutant *CALR* variants, including an association of type 2 vs type 1 variants with higher platelet count in ET¹² and worse prognosis in PMF.¹³

JAK2 mutations in ET are often accompanied by distinct biological and clinical characteristics,¹ suggesting the possibility of a *JAK2* mutation-associated disease continuum that is phenotypically patterned by additional genetic or biologic changes. Consistent with this concept, some have argued that PV and *JAK2*-mutated ET are different phases of the same disease and share similar natural history, including survival.^{5,14} The current study addresses this issue by comparing long-term survival and blast transformation (BT) rates between PV, ET, and PMF, in the context of their specific *JAK2/MPL/CALR* mutational status; we also examined the impact of *JAK2/MPL/CALR* mutational status on long-term disease outcome in ET and PMF.

Methods

The current study was approved by the institutional review boards of Mayo Clinic (Rochester, MN), University of Florence (Florence, Italy), and Papa Giovanni XXIII Hospital (Bergamo, Italy) and conducted in accordance with the Declaration of Helsinki. To obtain mature survival data, study eligibility criteria included a diagnosis date prior to 2006 for ET and PV and 2011 for PMF. In addition, for ET and PMF, only those patients whose mutational status, in terms of *JAK2*, *CALR*, or *MPL*, was known were included in the current study. The performance of mutation screening was solely based on

availability of archived DNA and no other selection bias was introduced. Diagnoses of ET, PV, PMF, and BT were according to the 2008 World Health Organization (WHO) criteria.^{15,16} Previously published methods were used for *CALR*, *JAK2*, and *MPL* mutation analyses.⁶

All statistical analyses considered clinical and laboratory parameters obtained at diagnosis or within 1 year of diagnosis. Differences in the distribution of continuous variables between categories were analyzed by either Mann-Whitney or Kruskal-Wallis test. Patient groups with nominal variables were compared by χ^2 test. All patients, including those from the Mayo Clinic and the 2 Italian centers, were followed until death, leukemic transformation, or last clinic visit if they were currently alive. In addition, follow-up information on the patients who are alive was updated by directly contacting patients or their physicians. Survival analysis was considered from the date of diagnosis to date of death (uncensored) or last contact (censored). Leukemia-free survival (LFS) calculations considered BT as the uncensored variable. Survival curves were prepared by the Kaplan-Meier method and compared by the log-rank test. Observed survival in ET was compared with the expected survival of the age- and sex-matched US total population. The rate of BT was calculated as the cumulative incidence of transformation, accounting for the competing risk of death.¹⁷ The Cox proportional hazard regression model was used for multivariable analysis. *P* values < .05 were considered significant. All analyses were conducted using the Stat View (SAS Institute) or SAS version 9.2 (SAS Institute) statistical packages.

Results

One thousand five hundred eighty-one patients were included in the current study and were recruited from the Mayo Clinic (*n* = 826) and 2 centers from Italy (*n* = 755; 598 from Florence and 157 from Bergamo). The comparison of survival between ET, PV, and PMF was first analyzed using the Mayo cohort and the results validated using the Italian cohort; the 2 cohorts were considered together for examining the prognostic implications of mutational status in ET and PMF, to optimize the sample sizes for patients with the less frequent mutational categories.

The 826 Mayo patients included 292 with ET, 267 PV, and 267 PMF (Table 1). The 755 patients from Italy included 284 with ET (median age, 54 years; 68% females), 310 PV (median age 58 years; 46% females), and 161 PMF (median age, 64 years; 32% females) (supplemental Table 1, see supplemental Data available at the *Blood* Web site). All 157 patients from Bergamo had PV and the 445 Italian patients with ET or PMF were all recruited from the University of Florence.

Presenting features: ET vs PV vs PMF

Table 1 outlines clinical and laboratory features at diagnosis (or within 1 year of diagnosis) for the 826 patients from the Mayo Clinic, stratified by MPN subtype. In addition to the expected differences in hemoglobin level and platelet count, other significant differences between ET, PV, and PMF included younger age in ET, preponderance of male sex in PMF, and higher leukocyte count in PV. Similar analysis restricted to *JAK2*-mutated cases revealed mostly similar results (supplemental Table 2). Supplemental Table 1 outlines comparative results for the patients from Italy, which were mostly similar, with few exceptions.

Presenting features: *JAK2* vs *CALR* vs *MPL* mutated vs triple-negative ET

Table 2 lists the presenting features in the combined Mayo-Italian cohort of patients with ET (*n* = 576). Compared with *JAK2*-mutated

Table 1. Presenting clinical and laboratory features of 826 Mayo Clinic patients with ET vs PV vs PMF

Variables	ET, n = 292	PV, n = 267	PMF, n = 267	P		
				ET vs PV	ET vs PMF	PV vs PMF
Age, median (range), y	55 (15-91)	64 (19-95)	63 (14-87)	<.0001	<.0001	.6
Age ≥60 y, n (%)	123 (42.1)	157 (58.8)	163 (61)	<.0001	<.0001	.6
Females, n (%)	173 (59.2)	137 (51.3)	102 (38.2)	.06	<.0001	.002
Hemoglobin, median (range), g/dL	13.9 (6.9-17.9)	18.4 (15.1-24.5)	10.6 (5.8-16.1)	<.0001	<.0001	<.0001
Leukocytes, median (range), ×10 ⁹ /L	9.6 (2.8-53.4)	11.8 (3.8-171.6)	8.6 (0.8-146.6)	<.0001	.1	<.0001
Platelets, median (range), ×10 ⁹ /L	1000 (454-3460)	467 (37-1720)	253 (12-2466)	<.0001	<.0001	<.0001
Risk stratification,* %						
Low	37	25	17			
Intermediate	40	32				
Intermediate-1			22			
Intermediate-2			33			
High	23	43	28			
Leukocytes, ≥11 × 10 ⁹ /L, %	33.1	56.5	36.3	<.0001	.4	<.0001
Platelets, >1000 × 10 ⁹ /L, %	52.4	7.1	2.2	<.0001	<.0001	.008
Abnormal karyotype, "N" evaluable = 610, n (%)	16 (7.7)	26 (18.3)	87 (33.4)	.003	<.0001	.001
Palpable splenomegaly, %	23.6	37.3	72.6	.0005	<.0001	<.0001
Microcirculatory symptoms, "N" evaluable = 510, n (%)	52 (17.8)	89 (40.8)	NA	<.0001	NA	NA
Mutational status, n (%)				NA	.02	NA
JAK2	157 (53.8)		149 (55.8)			
CALR	89 (30.5)		64 (24)			
MPL	8 (2.7)		21 (7.9)			
Triple negative	38 (13)		33 (12.3)			

NA, not available.

*Risk stratification in PMF was according to the Dynamic International Prognostic Scoring System plus; in ET, according to the International Prognostic Scoring System; and in PV, according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria. References for these prognostic criteria are included in the main text.

cases, *CALR*-mutated ET patients displayed younger age, male sex, higher platelet count, lower hemoglobin level, lower leukocyte count, and lower incidence of thrombosis. Triple-negative ET patients also displayed younger age, lower hemoglobin level, lower leukocyte count, and lower incidence of thrombosis, compared with *JAK2*-mutated cases. Comparison of triple-negative and *CALR*-mutated ET patients showed the latter to be associated with male sex and higher platelet count. *MPL*-mutated cases were similar to *JAK2*-

mutated cases in terms of age and gender distribution and thrombosis risk but displayed lower hemoglobin level.

Presenting features: JAK2 vs CALR vs MPL mutated vs triple-negative PMF

Table 2 lists the presenting features in the combined Mayo-Italian cohort of patients with PMF (n = 428). Compared with

Table 2. Presenting features of 1004 patients with ET or PMF, stratified by their mutational status

	JAK2 mutated (A)	CALR mutated (B)	Triple negative (C)	MPL mutated (D)	P			
					A vs B	A vs C	B vs C	A vs D
ET, N = 576								
No. of patients	336	134	84	22				
Age, median (range), y	58 (16-88)	49 (13-91)	47 (16-81)	57 (22-85)	<.0001	.0004	.8	1.0
Age ≥60 y, n (%)	157 (47)	36 (27)	29 (34)	8 (36)	<.0001	.04	.2	.3
Females, n (%)	227 (68)	66 (49)	61 (73)	13 (59)	.0002	.4	.0007	.4
Hemoglobin, median (range), g/dL	14.3 (9.8-17.9)	13.5 (6.9-16.4)	13.2 (8.4-16.7)	13.8 (9.0-16.0)	<.0001	<.0001	.7	.02
Leukocytes, median (range), ×10 ⁹ /L	9.6 (3.5-53.4)	8.5 (2.6-32.6)	8.3 (2.8-15.4)	7.4 (4.0-17.7)	.0007	.0006	.6	.07
Platelets, median (range), ×10 ⁹ /L	841 (469-3000)	1000 (454-3460)	854 (500-3300)	900 (685-2249)	<.0001	.4	.003	.1
Leukocytes ≥11 × 10 ⁹ /L, %	31	24	20	26	.1	.04	.5	.6
Platelets >1000 × 10 ⁹ /L, %	29	54	38	41	<.0001	.1	.02	.2
Thrombosis history, %	37	27	20	45	.04	.004	.3	.4
PMF, N = 428								
No. of patients	258	92	52	26				
Age, median (range), y	65 (28-90)	54 (18-83)	67 (14-88)	60 (29-80)	<.0001	.3	<.0001	.046
Age ≥60 y, n (%)	173 (67%)	35 (38%)	39 (75%)	15 (58%)	<.0001	.3	<.0001	.3
Females, n (%)	88 (34%)	39 (42%)	18 (35%)	9 (35%)	.1	.9	.4	1.0
Hemoglobin, median (range), g/dL	11.0 (5.4-17.5)	11.3 (8.0-15.5)	9.6 (5.2-13.5)	10.2 (6-14)	.3	<.0001	<.0001	.08
Leukocytes, median (range), ×10 ⁹ /L	9.9 (0.8-106.1)	8.0 (1.8-40.0)	6.7 (1.4-146.6)	5.8 (2.5-42.0)	.003	.1	.7	.03
Platelets, median (range), ×10 ⁹ /L	260 (12-2466)	387 (15-1563)	147 (14-900)	179 (31-925)	<.0001	.001	<.0001	.06
Leukocytes ≥11 × 10 ⁹ /L, %	46	23	41	33	.0002	.5	.03	.2
Platelets >1000 × 10 ⁹ /L, %	3	9	0	0	.02	.2	.03	.4

Percentages are rounded up to the nearest whole percent.




Figure 1. Comparison of survival in 826 Mayo Clinic patients with ET vs PV vs PMF. Survival in ET was also compared with the age- and sex-matched US population.

JAK2-mutated cases, *CALR*-mutated PMF patients displayed younger age, higher platelet count, and lower leukocyte count. Triple-negative PMF patients displayed lower hemoglobin level and lower platelet count, compared with *JAK2*-mutated cases. Comparison of *CALR* and triple-negative PMF patients showed the former to be younger and display higher hemoglobin and platelet counts. Compared with *JAK2*-mutated cases, *MPL*-mutated PMF patients were younger and displayed lower leukocyte count.

Cytogenetic information was available for the Mayo Clinic PMF patients and showed an abnormal karyotype in 33% with no difference between the *JAK2/CALR/MPL* mutational categories ($P = .43$); there was also no difference in the distribution of normal vs favorable vs unfavorable cytogenetic abnormalities ($P = .46$).

Clinical course

Among the 826 Mayo patients, 475 (58%) were followed until death, including 139 (48%) with ET, 164 (61%) with PV, and 172 (64%) with PMF; the median follow-up time for living patients was 17.3 years for ET (range, 6.8-43.6), 11.8 years for PV (range, 8.3-39.3) and 7.7 years for PMF (range 3.3-26). BT was reported in 64 Mayo patients, including 34 (12.7%) with PMF, 18 (6.7%) with PV, and 12 (4.1%) with ET; fibrotic transformations were reported in 63 patients including 34 (12.7%) with PV and 29 (9.9%) with ET.

Among the 755 Italian patients, 168 (22%) were followed until death, including 24 (9%) with ET, 84 (27%) with PV, and 60 (37%) with PMF. The median follow-up time for living patients in the Italian cohort was 10.7 years for ET, 11.1 years for PV, and 4.8 years for PMF; BT was reported in 33 patients, including 19 (11.8%) with PMF, 10 (3.2%) with PV, and 4 (1.4%) with ET. Fibrotic transformations were reported in 91 Italian patients including 65 (21%) with PV and 26 (9.2%) with ET. Polycythemic conversions were infrequent in both the Mayo ($n = 9$; 3%) and Italian ($n = 2$; 1%) cohorts.

Considering the fact that the study population was selected based on diagnosis dates of prior to 2006 for ET and PV and 2011 for PMF, there was not much difference in treatment approaches between the Mayo Clinic and the 2 Italian centers. In all instances, hydroxyurea was the primary cytoreductive agent used for high-risk PV or ET and PMF. Other frequently used drugs included aspirin for PV and ET

and a spectrum of agents for PMF-associated anemia, including androgen preparations, erythropoiesis-stimulating agents, prednisone, danazol, and thalidomide.

Survival: ET vs PV vs PMF


Primary analysis of survival data, for comparison of ET vs PV vs PMF, was performed using the Mayo Clinic cohort of 826 patients, where the majority (58%) was followed until death, thus ensuring mature survival data (Figure 1). Median survivals were 19.8 years for ET, 13.5 for PV (hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.4-2.2), and 5.9 for PMF (HR, 4.5; 95% CI, 3.5-5.7). The corresponding median survivals for patients younger than age 60 years were 32.7 years for ET, 23.8 years for PV, and 14.6 years for PMF ($P < .001$; supplemental Figure 1). Despite the very long survival estimates in patients with ET, their life expectancy remained inferior to the age- and sex-matched US population (Figure 1; $P < .001$).

The survival advantage of ET over PV was not affected by age (HR, 1.5; 95% CI, 1.2-1.9), sex (HR, 1.8; 95% CI, 1.4-2.3), or mutational status (HR, 1.7; 95% CI, 1.3-2.2) and was similarly demonstrated by a separate analysis of the Italian patient cohort ($n = 755$; supplemental Figure 2). The HRs (95% CI) for the Italian cohort, compared with ET, were 12.3 (7.6-20.0) for PMF and 3.1 (2.0-4.9) for PV; the corresponding values for analysis restricted to the 598 patients from Florence were 10.9 (6.7-17.8) and 2.3 (1.3-3.8).

BT and fibrotic progression: ET vs PV vs PMF

In the Mayo cohort, the cumulative incidence of BT, with death as a competing risk, was 3.8% for ET (95% CI, 1.3-6.2), 6.8% for PV (95% CI, 3.3-10.2), and 14.2% for PMF (95% CI, 9.5-18.6) (Figure 2). The difference was significant for ET vs PMF ($P = .002$) and for PV vs PMF ($P = .03$). The difference between ET and PV was of borderline significance (0.16). Calculation of LFS without competing risk adjustment showed worse outcome in both PMF (HR, 9.4; 95% CI, 4.6-19.3) and in PV (HR, 2.3; 95% CI, 1.1-4.7), compared with ET. The corresponding HRs (95% CI), during separate analysis of *JAK2*-mutated cases, were 18.8 (6.4-55.4) and 2.9 (1.1-7.9). A similar analysis of LFS in the Italian patient cohort

Figure 2. Comparison of BT rates among 826 Mayo Clinic patients with ET vs PV vs PMF, which includes accounting for death as a competing risk. Cumulative incidences of BT (95% CI) were 0.038 (0.013-0.062) for ET, 0.068 (0.033-0.102) for PV, and 0.142 (0.095-0.186) for PMF; *P* values were .03 for PV vs PMF at 20 years, .002 for ET vs PMF at 20 years, and .16 for ET vs PV at 20 years.



also showed a significant difference between PMF and ET (HR, 19.1; 95% CI, 6.3-57.7) but the difference between PV and ET did not reach statistical significance (HR, 2.3; 95% CI, 0.7-7.3).

Among the Italian cohort of 594 patients with PV (n = 310) and ET (n = 284), 91 fibrotic transformations were reported, including 65 (21%) in PV and 26 (9.2%) in ET (*P* < .0001). In contrast, comparison of fibrotic progression rates in the Mayo cohort was not significantly different between ET (10.3%) and PV (12.5%).

Mutation-specific survival: ET vs PV vs PMF

Figure 3 depicts survival data comparisons, using the Mayo patient cohort, between PV and patients with ET and PMF stratified by the 2 most frequent mutations: *JAK2* and *CALR*. The figure illustrates the inferior survival in both PV (HR 1.6, 95% CI 1.2-2.1) and *JAK2*-mutated PMF (HR, 6.2; 95% CI, 4.5-8.5), compared with *JAK2*-mutated ET. This difference in survival between PV and *JAK2*-

mutated ET remained significant during multivariable analysis that included both age and sex (*P* = .007; HR, 1.5; 95% CI, 1.1-1.9).

In univariate analysis, there was no significant difference in survival between PV and *CALR*-mutated PMF (*P* = .54; Figure 3); however, survival was shown to be worse in *CALR*-mutated PMF (median age, 54 years), compared with PV (median age, 64 years; *P* < .001), when the analysis was adjusted for age (HR, 1.6; 95% CI, 1.1-2.4). The *JAK2* mutation-specific survival difference between ET, PV, and PMF was similarly demonstrated in the Italian patient cohort (supplemental Figure 3); HRs (95% CI), compared with *JAK2*-mutated ET, were 15.1 (8.0-28.5) for *JAK2*-mutated PMF and 2.7 (1.6-4.6) for PV.

Mutational status and disease outcome in PMF

To optimize sample size for comparison of survival among specific mutational groups in PMF, we analyzed the Mayo and Italian cohorts together. This resulted in a total number of 428 patients with *JAK2*




Figure 3. Survival data comparisons in Mayo Clinic patients with PV vs *JAK2*- or *CALR*-mutated ET or PMF. *P* values were <math><.01</math> for (1) *JAK2*-mutated PMF vs *CALR*-mutated PMF, PV, *JAK2*-mutated ET or *CALR*-mutated ET, (2) *CALR*-mutated PMF vs *CALR*-mutated ET or *JAK2*-mutated ET, and (3) PV vs *JAK2*-mutated or *CALR*-mutated ET. Univariate analysis did not show a difference between *JAK2* and *CALR*-mutated ET (*P* = .28) or *CALR*-mutated PMF and PV (*P* = .54).




Figure 4. Comparison of survival among 428 patients with PMF stratified by their mutational status.

($n = 258$; 60%), *CALR* ($n = 92$; 22%), *MPL* ($n = 26$; 6%) mutated or triple-negative ($n = 52$; 12%) mutational status. Triple-negative patients displayed significantly worse survival (median, 2.3 years), compared with *CALR* (median, 15.9 years; HR, 0.2; 95% CI, 0.1-0.3), *JAK2* (median, 5.9 years; HR, 0.5; 95% CI, 0.4-0.7), or *MPL* (median, 9.9 years; HR, 0.3, 95% CI, 0.2-0.6) mutated cases (Figure 4); these differences remained significant when analysis was adjusted for age and sex. Conversely, survival was significantly better in *CALR*-mutated patients, compared with triple-negative (HR, 5.1; 95% CI, 3.2-8.0) and *JAK2* (HR, 2.5; 95% CI, 1.7-3.7) mutated cases; the difference in survival between *CALR*- and *MPL*-mutated PMF did not reach significance level (HR, 1.6; 95% CI, 0.9-3.0).

Among the 92 *CALR* mutated PMF patients recruited from the Mayo Clinic and University of Florence, 72 harbored type 1, 10 type 2, and 10 other *CALR* variants. Survival was significantly better in type 1, compared with both type 2 ($P = .03$) *CALR* variant and mutant *JAK2* ($P < .0001$). Survival was not different between type 2 *CALR* and *JAK2* mutations ($P = .3$) or mutant *JAK2* and other *CALR* variants ($P = .7$).

LFS in PMF was significantly worse in the presence of triple-negative mutational status, compared with *CALR* (HR, 0.1; 95% CI, 0.05-0.35), *JAK2* (HR, 0.4; 95% CI, 0.2-0.7) and *MPL* (HR, 0.3; 95% CI, 0.1-0.9) mutated status. Conversely, *CALR*-mutated patients were at lesser risk of leukemic transformation, compared with triple-negative (HR, 7.6; 95% CI, 2.8-20.2) and *JAK2* (HR, 2.7; 95% CI, 1.1-6.6) mutated cases, but not when compared with *MPL*-mutated cases (HR, 1.9; 95% CI, 0.5-7.7).

Mutational status and disease outcome in ET

The 576 patients with ET included *JAK2* ($n = 336$; 58%), *CALR* ($n = 134$; 23%), *MPL* ($n = 22$; 4%), mutated or triple-negative ($n = 84$; 15%) cases. Survival differences between mutational categories, noted during univariate analyses (P values of .04 and .02 in favor of triple-negative vs *JAK2*- and *MPL*-mutated cases, respectively), were fully accounted for by differences in age distribution (age-adjusted P values were .38 and .21, respectively). Similarly, a near-significant ($P = .06$) difference in age-adjusted survival between triple-negative and *CALR*-mutated cases ($P = .06$) became

insignificant when adjusted for gender ($P = .31$). LFS in ET was not affected by mutational status.

A total of 55 (9.5%) fibrotic transformations were documented among the 576 ET patients from Mayo and Italy. These included 27 (8%) of 336 *JAK2*-mutated, 18 (13.4%) of 134 *CALR*-mutated, 6 (27%) of 22 *MPL*-mutated, and 4 (4.8%) of 84 triple-negative cases ($P = .004$); the apparently significant difference was attributed to the higher transformation rate in *MPL*-mutated ET and the P value between the other 3 mutational categories was .06.

Discussion

Among the *BCR-ABL1*-negative MPN, ET is generally considered to have the best prognosis and PMF the worst.¹⁸ In this regard, recent reports have underscored the prognostic relevance of strict adherence to WHO-defined morphologic criteria, in distinguishing ET from both prefibrotic PMF and masked PV.^{19,20} The recent discovery of *CALR* mutations in *JAK2* and *MPL* unmutated MPN,²⁻³ their remarkable specificity to ET and PMF, and their potential relevance to disease outcome warranted a revisit on the prognostic interrelationship between morphologically defined PV, ET, and PMF.

The current study, which is distinguished by the consideration of strictly WHO-defined MPN that is fully annotated for *JAK2/CALR/MPL* mutational status, establishes the superiority of morphologically defined ET to PV, regardless of mutational status. We also show reduced life expectancy in ET, which was suggested in a previous population-based study.¹⁸ Mature survival data in patients younger than age 60 years revealed very long median survivals of ~33 years for ET, 24 years for PV, and 15 years for PMF. The particular observation underscores the need to respect the generally stable clonal biology in ET and PV and avoid subjecting patients to investigational drug therapy whose long-term ill effects are unknown.

The second major point from the current study is the demonstration of similar overall and LFS data between *JAK2*- and *CALR*-mutated ET, both of which were significantly better than those of PV. Also, patients with *JAK2*-mutated ET who converted to bona fide PV were rare in both the Mayo and Italian cohorts. These observations do not support

the concept of a disease continuum between *JAK2*-mutated ET and PV and, instead, suggest 2 separate disease entities that are primarily distinguished by their morphologic traits. In other words, PV and ET are not distinguished by their genetic profile but by their phenotypic characteristics and clinical course.

The respectively favorable and unfavorable prognostic impact of *CALR*-mutated and triple-negative mutational status in PMF is therapeutically relevant. Obviously, treatment decisions should also account for the Dynamic International Prognostic Scoring System–plus risk stratification²¹ and additional prognostically detrimental mutations.^{10,11,22} The apparently higher incidence of fibrotic transformations in *MPL*-mutated ET warrants further investigation.

In conclusion, currently known mutations have yet to overshadow the need for morphologic distinction of ET from PV, in terms of not only diagnostic but also prognostic relevance. In other words, determination of *JAK2/CALR* mutational status alone, without morphologic examination, is not sufficient to differentiate PV from *JAK2* mutant ET. On the other hand, distinguishing morphologically defined ET into *JAK2* and *CALR* subtypes carries limited prognostic relevance, in terms of survival and BT. In contrast, *JAK2/CALR/MPL* mutational status provides significant prognostic information in PMF, which should be further clarified in view of the possible difference in prognostic contribution from distinct *CALR* variants.

Acknowledgments

The study from the Mayo Clinic was supported by the Mayo Clinic Harvey-Yulman Charitable Foundation for Myelofibrosis Tissue Bank and Clinical Database of Molecular and Biological

Abnormalities. The study in Florence was supported by a special grant from Associazione Italiana per la Ricerca sul Cancro (AIRC 5 per Mille) to AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) (#1005; for a description of the AGIMM project and list of investigators, see www.progettoagimm.it). This work was also supported also by Fondo per gli Investimenti della Ricerca di Base (FIRB; RBAP11CZLK) and Progetti di ricerca di interesse nazionale (PRIN; 2010NYKNS7) (A.M.V.).

Authorship

Contribution: A.T. designed the study, contributed patients, extracted data, performed statistical analysis, wrote the paper, and approved the final draft of the manuscript; A.M.V., P.G., and T.B. designed the study, contributed patients, extracted data, and approved the final draft of the manuscript; L.P., N.G., R.F., A.R., G.F., and A.P. contributed patients, extracted data, and approved the final draft of the manuscript; C.F., E.A.W., A.A.B., and T.L.L. performed mutation analysis, extracted data, and approved final draft of manuscript; D.R.L. performed statistical analysis; R.P.K. provided resources for cytogenetic analysis and expertise in result interpretation; and C.A.H. and J.T. reviewed bone marrow pathology.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Ayalew Tefferi, Division of Hematology, Department of Medicine, Mayo Clinic, Rochester MN 55905; e-mail: tefferi.ayalew@mayo.edu.

References

- Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. *J Clin Oncol*. 2011;29(5):573-582.
- Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med*. 2013;369(25):2379-2390.
- Nangalia J, Massie CE, Baxter EJ, et al. Somatic *CALR* mutations in myeloproliferative neoplasms with nonmutated *JAK2*. *N Engl J Med*. 2013;369(25):2391-2405.
- Rotunno G, Mannarelli C, Guglielmelli P, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. *Blood*. 2014;123(10):1552-1555.
- Rumi E, Pietra D, Ferretti V, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. *JAK2* or *CALR* mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. *Blood*. 2014;123(10):1544-1551.
- Tefferi A, Lasho TL, Finke CM, et al. *CALR* vs *JAK2* vs *MPL*-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. *Leukemia*. 2014;28(7):1472-1477.
- Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long-term survival in essential thrombocythemia [published online ahead of print May 5, 2014]. *Leukemia*.
- Fu R, Xuan M, Zhou Y, et al. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment [published online ahead of print April 15, 2014]. *Leukemia*.
- Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of *JAK-STAT* pathway activation in myeloproliferative neoplasm pathogenesis. *Blood*. 2014;123(22):e123-e133.
- Tefferi A, Guglielmelli P, Lasho TL, et al. *CALR* and *ASXL1* mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. *Leukemia*. 2014;28(7):1494-1500.
- Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients [published online ahead of print February 19, 2014]. *Leukemia*.
- Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 vs type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. *Am J Hematol*. 2014;89(8):E121-E124.
- Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. *Leukemia*. 2014;28(7):1568-1570.
- Campbell PJ, Scott LM, Buck G, et al; United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythemia and relation to polycythaemia vera based on *JAK2* V617F mutation status: a prospective study. *Lancet*. 2005;366(9501):1945-1953.
- Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood*. 2009;114(5):937-951.
- Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. *Am J Hematol*. 2010;85(1):62-69.
- Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med*. 1999;18(6):695-706.
- Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. *J Clin Oncol*. 2012;30(24):2995-3001.
- Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. *J Clin Oncol*. 2011;29(23):3179-3184.
- Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. *Am J Hematol*. 2014;89(1):52-54.
- Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol*. 2011;29(4):392-397.
- Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. *Blood*. 2014;123(14):2220-2228.